Increased risk of hypotension, hyperkalemia & changes in renal function in combination with angiotensin II receptor blockers or aliskiren. Hyperstimulated renin-angiotensin system. Patients with liver disease; at particular risk from a pronounced reduction in blood pressure. Renal function, electrolyte & haematological monitoring. May impair ability to drive or operate machinery. Lactation. Elderly.